Piper Boosts Moderna Target To $166 After 'Impressive' Vaccine Response

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Moderna to $166 from $136 and reiterates an Overweight rating on the shares after the company reported that mRNA-1273 showed 94.5% efficacy against COVID-19.